Clinical Virtues Of Carotid Stenting Prior To CREST Finale Debated At ACC
This article was originally published in The Gray Sheet
Executive Summary
Carotid stenting should be the standard of care for symptomatic and asymptomatic patients prior to completion of the Carotid Revascularization Endarterectomy Stenting Trial (CREST), Gary Roubin, MD, New York University School of Medicine said.
You may also be interested in...
PercuSurge, MedNova, AngioGuard Battle For Inclusion In CREST Study
PercuSurge, AngioGuard and MedNova, three of the frontrunners in the race to have their distal protection devices used in the upcoming Carotid Revascularization Endarterectomy Stenting Trial (CREST), exhibited their wares at the Jan. 22-26 International Symposium on Endovascular Therapy (ISET) in Miami Beach.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.